Iovance Reports 50% Response Rate for Soft Tissue Sarcoma Treatment in 8 Patients
Key Facts
Iovance Biotherapeutics said on October 26, 2026, that its cell therapy lifileucel achieved a confirmed objective response rate of 50% among the first 8 evaluable patients in an exploratory study of advanced soft tissue sarcoma. The data included patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, and were presented orally at the ESMO 2026 conference. The company said all four responses were still ongoing at the data cutoff. The result offers an early signal of the therapy’s activity in these two sarcoma types, but is based on a small patient group. The next test will be whether the signal is repeated in the registrational study the company began activating during the second quarter of 2026.
The latest result followed early data showing a confirmed response rate of 50% among the first 6 evaluable patients. The update added two patients to the analysis group while the rate remained at the same level. That means the number of confirmed responses rose to 4 of 8 patients in the current analysis, with all four responses ongoing at the data cutoff. The initial signal had previously prompted the company to start a registrational study dedicated to undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. The comparison between the two analyses remains a description of the study sample’s progression, not a treatment comparison with another group.
The SARATOGA trial targets patients with one of the two advanced cancer types after prior treatment and is a multicenter, open-label Phase 2 study. The company describes it as a registrational study to assess the efficacy and safety of lifileucel in this population. The objective response measure tracks the proportion of patients whose tumors shrink or disappear under RECIST v1.1. The company designated this rate as the trial’s primary endpoint, with an independent review committee set to assess responses. This design provides a path to validate the exploratory sample’s result in a broader study, using a defined assessment standard and independent review.
The company places the results in the context of limited options after prior treatment; studies it cited indicate that response rates to current second-line therapies are below 5%. This comparison highlights the treatment need the trial aims to address, but does not make the two studies’ results directly comparable. The current lifileucel data come from a small exploratory sample, while the reference studies differ in design and patient populations. The reported rate therefore remains an early indicator of therapeutic activity, not a final estimate of efficacy. SARATOGA is expected to provide a more structured test of the result in previously treated patients.
The U.S. Food and Drug Administration granted lifileucel Fast Track designation for soft tissue sarcoma in August 2026. The designation allows for expedited regulatory communication about a treatment targeting a serious condition and unmet medical need, but does not constitute approval for use in this disease. The therapy has had accelerated approval from the agency since February 16, 2024, for adults with unresectable or metastatic melanoma after prior treatment with a PD-1 inhibitor. Its melanoma use includes additional requirements for patients with a BRAF V600 mutation. The sarcoma pathway remains separate from that approval and depends on the registrational trial’s results and subsequent regulatory decisions.
In the market, Iovance shares closed at $14.09 on October 23, 2026, the latest recorded close before the results announcement. These data do not establish that the shares rose after the announcement, contrary to what appeared in the earlier draft. The result keeps the focus on tracking SARATOGA’s progress, following its start in the second quarter of 2026, and on response-rate readings under RECIST v1.1 reviewed by the independent committee. The disclosure did not specify a date for a subsequent results update. The durability of responses and findings from a larger patient group will be among the factors assessed when new data are released.